Being a great
partner means
everything to us.
We believe in supporting our companies however we can, in both good and challenging times.
We're ready to help you
send us a messageWe are
principled and
patient investors.
We leverage our decades of experience to promote
the growth of our companies.
What we offer
Allan Mandelzys PhD, MBA
Chief Operating Officer and Chief Development Officer
Ian Jacobson
Founder and PartnerIan has over 43 years of pharmaceutical industry experience.
Prior to founding Juno/CPoint in 2010, Ian worked for Arrow Pharmaceuticals as the CEO of Cobalt Pharmaceuticals from 2000 – 2010. He was instrumental in the development of Arrow’s international business units in South Africa and Brasil. As CEO of Cobalt, Ian was responsible for managing over $300 million in annual Canadian sales and played a key role in facilitating the sale of Arrow to Watson Pharmaceuticals (now Teva) in June 2009 for over $2.4 billion USD.
Prior to his work at Arrow, Ian was Executive Vice President and General Manager of Genpharm, Canada. He was a Senior Executive in the international generics business of Amerpharm/Merck KGaA (now Mylan/Viatris) and served in the office of the President of Par Pharmaceuticals (US) for Merck Generics
Craig Podolsky
Founder and PartnerCraig Podolsky is a founding partner at CPoint Capital and founder and president of the Juno Group of Companies (since 2012). Craig has over 18 years of experience seeding, investing and acquiring companies in the healthcare industry with a focus on generic and specialty pharmaceuticals and medical devices.
Prior to CPoint Capital and Juno he worked in various roles at Cobalt Pharmaceuticals. Craig earned his HBA from the Richard Ivey School of Business at the University of Western Ontario. He currently serves on the boards of Aspire Pharmaceuticals, Contura, Juno Pharmaceuticals Corp, and Conavi Medical.
Allan Mandelzys PhD, MBA
Chief Operating Officer and Chief Development OfficerDr. Mandelzys has enjoyed more than 28 years in the biotech, specialty and generic pharmaceutical sector, with leadership roles spanning research and product development, business and corporate development and general management of both private and publicly traded companies.
Dr. Mandelzys joined CPoint Capital as a partner in 2022 and is also the Chief Operating and Development Officer for Juno Pharmaceuticals. He has been Chairman of Searchlight Pharmaceuticals since 2018 and a member of the Board of Matrizyme Pharma Corp., Exactis Innovation and Omega Laboratories, as well as a Board observer at numerous private entities. He is a former Board member of Clementia Pharmaceuticals up until its acquisition by Ipsen in 2019 and of Bedrocan Cannabis Corporation up until its amalgamation into Canopy Growth Corporation in 2015.
Prior to joining Juno in 2022, Dr. Mandelzys served as a strategic business and scientific consultant to the biotech industry, often assuming interim leadership positions within organizations. Prior to his consulting roles, Dr. Mandelzys served as CEO and director at Thallion Pharmaceuticals up until its acquisition by Bellus Health in 2013. Dr. Mandelzys served as vice president of business development at Labopharm from 2000 to 2006 through its IPO listing on the NASDAQ and held senior research and business development roles with Allelix Biopharmaceuticals from 1995 to 2000 through its acquisition by NPS Pharmaceuticals.
Dr. Mandelzys earned a PhD in physiology and an MBA from McGill University, and holds a BSc from the University of Toronto. He received his post-doctoral training at the Roche Institute of Molecular Biology.
Chris Ichiyen CPA, CA
VP FinanceChris has more than 17 years of healthcare and pharmaceutical industry experience. Prior to CPoint he worked in progressive roles with Cobalt/Watson/Actavis Pharma which culminated as the Canadian Finance Country Head with Actavis Pharma and was a member of the leadership team managing cross-functional initiatives in a complex and results oriented environment.
During that time he gained experience in mergers and acquisitions and post acquisitions integration including in-depth support on $1.8 billion of transactions. Chris earned his CPA/CA while at KPMG.
Portfolio
Juno OTC is an In-licensor and distributor of private label over-the-counter (OTC) products sold via leading domestic pharmacy chains.
COSM Medical is developing Gynethotics™, the world’s first patient-matched gynecological prosthetic for female pelvic floor disorders.
Utilizing its proprietary hydrogel technology Contura has development Arthrosamid®, a new, long lasting non-degradable bio-scaffold treatment for osteoarthritis (OA) of the knee utilizing.
The Kahma Group is a diversified South African healthcare group that has a wide range of interests that form the foundation of healthcare including, vaccines, medical consumables, dental products, pharmaceuticals and medical devices.
Your Choice Therapeutics is developing the first non-hormonal and convenient birth control for men.
Searchlight Pharma is a Canadian-based specialty healthcare company dedicated to improving human health and wellness through the acquisition, commercialization, and focused development of unique healthcare products.
Trinity Pharma is a pharmaceutical company with a focus on niche retail generic drugs, sold through pharmacy channels.
Contura International is a Danish develepor and manufacturer of long-lasting injectable hydrogels.
Juno South Africa is a specialty pharmaceutical company with a focus on niche injectable generic drugs sold through hospital channels.
Kye Pharma is a growing specialty pharmaceutical company that identifies areas of significant clinical unmet need and seeks to provide innovative high-value medicines to improve or extend the lives of patients across Canada.
Utilizing its proprietary hydrogel technology Contura has developed Arthamid Vet, which it uses to treat non-infectious causes of joint lameness in animals, including both early and late stages of osteoarthritis (OA) and degenerative joint diseases (DJD).
Fluid AI Medical AI-powered postoperative monitor Stream™ platform that continuously and non-invasevely analyzes postoperative would drainage.
Forus Therapeutics is a Canadian-based oncology pharmaceutical business the licenses in late stages products for commercilization in the Canadian market.
SFA Therapeutics currently has developed a new platform utilizing microbiome-derived metabolites as drugs for use in the treatment of chronic inflammatory diseases.
Omega is a specialty pharmaceutical licensor, developer, and manufacturer of injectable, biosimilar and high-value generics.
FEMSelect is a developer of the CE Marked EnPlace™ , a minimally invasive surgical system for suturing ligaments of the pelvic floor during Pelvic Organ Prolapse (POP) procedures.
Through Franklin, its diverse and growing community, Genoox accumulates the most relevant data base and delivers actionable, real-world genomic insights that impact lives, improve clinical outcomes, and shape the business of healthcare.
Exits
Simulare Medical is a developer and manufacturer of surgical simulators designed to help surgeons learn and advance procedure-specific functional experience.
Status:
Exited to Smile Train in 2020
Aspire Pharma is a UK based specialty pharmaceutical company devoted to delivering true value to patients, healthcare professionals and the NHS.
Status:
Sold majority of position to HIG Capital in 2021, but remain a minority shareholder
Juno Australia is an in-licensor and distributor of injectable generics and biosimilars.
Status:
Exited to Arrotex in 2023.
Bulkamid is a minimally invasive and long-lasting treatment option for bladder leaks caused by stress urinary incontinence (SUI).
Status:
Exited to Axonics in 2021
Let’s talk
CPOINT Capital Corp.
555 Richmond St W, Suite #512,
Toronto, ON M5V 3B1